Cigna Corporation (CGN.F)
| Previous close | 326.55 |
| Open | 326.55 |
| Bid | 331.15 x 20000 |
| Ask | 331.50 x 20000 |
| Day's range | 326.55 - 326.55 |
| 52-week range | 219.70 - 337.20 |
| Volume | |
| Avg. volume | 16 |
| Market cap | 95.108B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 20.32 |
| EPS (TTM) | 16.26 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 5.23 (1.60%) |
| Ex-dividend date | 04 Jun 2024 |
| 1y target est | N/A |
ZacksThe Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
PR NewswireNew Report: Employers Play Critical Role in Curbing Today's Youth Mental Health Crisis
Many American children struggling with mental health challenges do not receive optimal care, and it's exacerbating the damaging ripple effect on working parents and their employers, according to global health company The Cigna Group (NYSE: CI). A new report by the Evernorth Research Institute details the increasing significance of the youth mental health crisis, the challenges parents face, and provides a roadmap of specific steps employers can take to better support today's workforce.
ReutersCigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no out-of-pocket payment to eligible patients in the U.S. using its specialty pharmacy beginning in June, the health insurer said on Thursday. Cigna said it will stock high- and low-concentration biosimilar versions of Humira from drugmakers including Boehringer Ingelheim, Teva and Alvotech at its Accredo pharmacy.
